Boundless Bio, Inc. announced Q4 and full year 2025 financial results with net loss of $12.9 million and $58.2 million respectively, cash of $107.6 million providing runway into second half of 2028, and KOMODO-1 trial of BBI-940 open for enrollment. Christine Brennan, Ph.D. resigned from the Board effective March 3, 2026, for a new role at Johnson & Johnson Development Corporation with no disagreements.
Key takeaways
Cash, cash equivalents, and short-term investments $107.6 million as of December 31, 2025, runway into second half of 2028
Q4 2025 net loss $12.9 million vs $16.4 million in Q4 2024
Full year 2025 net loss $58.2 million vs $65.4 million in 2024
R&D expenses Q4 2025 $9.8 million vs $13.3 million Q4 2024; full year $44.8 million vs $55.3 million
KOMODO-1 first-in-human trial of BBI-940 open for enrollment in ER+/HER2- breast cancer and TNBC-LAR patients
Christine Brennan, Ph.D. resigned from Board effective March 3, 2026
Ceased enrollment in POTENTIATE trial of BBI-355 and BBI-825 in January 2026